68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Status No longer available

Clinical Trial Summary

The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01980732
Study type	Expanded Access
Source	Stanford University
Contact
Status	No longer available
Phase	N/A

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02441062` - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors	Phase 2
Completed	`NCT00580320` - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma	Phase 1
Completed	`NCT02575300` - Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors	Phase 2
Active, not recruiting	`NCT02441088` - Theranostics: 68GaDOTATOC and 90YDOTATOC	Phase 2
Terminated	`NCT00227136` - Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion	Phase 3
Terminated	`NCT00947167` - A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors	Phase 2
Terminated	`NCT02177773` - GA-68 DOTA-TOC of Somatostatin Positive Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT02795858` - A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors	Phase 2
Terminated	`NCT02859064` - Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres	Phase 2
Active, not recruiting	`NCT01731925` - A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors	Phase 2
Completed	`NCT00088595` - Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors	Phase 2
Completed	`NCT01619865` - Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors	Phase 1/Phase 2
Completed	`NCT01253161` - Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)	Phase 2
Terminated	`NCT02359500` - 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)	Phase 1
Not yet recruiting	`NCT01373736` - 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors	Phase 3